基线他法米迪使用对Vutrisiran在ATTR-CM中疗效的影响:HELIOS-B分析
HELIOS-B试验事后分析评估基线他法米迪使用是否改变Vutrisiran对转甲状腺素蛋白淀粉样变心肌病(ATTR-CM)的疗效。654例患者中259例(40%)基线使用他法米迪。主要终点在各 strata 的治疗效应方向一致(交互P=0.55),但基线使用他法米迪者效应量数值上较小。
要点
- Vutrisiran对主要终点的效应在各基线他法米迪 strata 间无显著交互(P=0.55)。
- 基线使用他法米迪者主要终点率比0.79(95%CI 0.51-1.21),未使用者0.67(95%CI 0.49-0.93)。
- KCCQ-OSS改善在基线使用他法米迪者中似减弱,需前瞻性联合治疗研究。
核心结论
- Vutrisiran对临床结局的效应在各基线他法米迪 strata 间一致,无显著交互,但基线使用稳定剂者效应量数值上小于单药治疗。
研究设计与样本
- HELIOS-B随机对照试验的事后分析,654例ATTR-CM患者随机接受Vutrisiran 25 mg或安慰剂每3个月一次至多36个月。
- 他法米迪使用允许并按基线分层,评估主要终点(全因死亡和复发性心血管事件)及次要终点。
主要发现
- 259例(40%)基线使用他法米迪,使用者稍年轻且基线6分钟步行距离和KCCQ-OSS更高。
- 主要终点率比:他法米迪组0.79(95%CI 0.51-1.21),无他法米迪组0.67(95%CI 0.49-0.93),交互P=0.55。
- 全因死亡、心血管事件和门诊心衰恶化交互P均>0.20,效应量数值上在他法米迪组较小。
- 6分钟步行距离在各 strata 均保持(交互P=0.24),KCCQ-OSS改善在基线他法米迪使用者中似减弱。
临床怎么用
- Vutrisiran疗效在各基线他法米迪 strata 间一致,支持其用于已接受他法米迪的ATTR-CM患者。
- 联合治疗的效果需前瞻性研究进一步验证。
局限性
- 为他法米迪使用非随机分层的事后分析,样本量有限。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vutrisiran, an RNA interference therapeutic that suppresses hepatic transthyretin production, improved survival and cardiovascular outcomes in transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy). Tafamidis, a transthyretin stabilizer, also improves clinical outcomes. Although combining these therapies is mechanistically appealing, clinical evidence supporting this approach is limited. OBJECTIVES: We sought to evaluate whether the treatment effects of vutrisiran differed according to baseline tafamidis use in HELIOS-B. METHODS: In HELIOS-B, patients with ATTR-CM were randomized to vutrisiran 25 mg or placebo every 3 months for up to 36 months, with tafamidis use permitted and stratified. We assessed treatment effects according to baseline tafamidis use for the primary outcome of all-cause mortality and recurrent cardiovascular events and secondary endpoints, including individual components of the primary outcome, composite of all-cause mortality, cardiovascular events and outpatient worsening heart failure events, functional capacity (6-minute walk distance), and health status (Kansas City Cardiomyopathy Questionnaire-overall summary score [KCCQ-OSS]). RESULTS: Among 654 participants, 259 (40%) were receiving tafamidis at baseline. Patients on tafamidis were slightly younger and had higher baseline 6-minute walk distance and higher KCCQ-OSS, while baseline characteristics were generally balanced between randomized groups. The treatment effect estimates of vutrisiran compared with placebo for the primary outcome were directionally consistent across baseline tafamidis strata (rate ratio: 0.79 [95% CI: 0.51-1.21] with tafamidis vs 0.67 [95% CI: 0.49-0.93] without), with no statistically significant interaction (Pinteraction = 0.55). Similar patterns were observed for all-cause mortality, cardiovascular events, and outpatient worsening heart failure (all Pinteraction > 0.20), although the magnitudes of the estimated effects were numerically smaller among patients receiving tafamidis at baseline. Vutrisiran preserved 6-minute walk distance in both baseline tafamidis strata (Pinteraction = 0.24), whereas improvement in KCCQ-OSS appeared attenuated among patients receiving tafamidis at baseline. CONCLUSIONS: Treatment effect estimates for vutrisiran on clinical outcomes were consistent across baseline tafamidis strata, with no statistically significant interaction according to baseline tafamidis use, with reduced effect size noted in those receiving baseline stabilizers in comparison to monotherapy. These data underscore the need for future prospective studies examining combination therapy in this population. (HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149).
引用
- Hamatani Y, Claggett BL, Cuddy SAM, et al. Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B. J Am Coll Cardiol. 2026. PMID: 42669070. doi:10.1016/j.jacc.2026.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。